Journal Menu
► ▼ Journal Menu-
- Marine Drugs Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Vol. 22 (2024)
- Vol. 21 (2023)
- Vol. 20 (2022)
- Vol. 19 (2021)
- Vol. 18 (2020)
- Vol. 17 (2019)
- Vol. 16 (2018)
- Vol. 15 (2017)
- Vol. 14 (2016)
- Vol. 13 (2015)
- Vol. 12 (2014)
- Vol. 11 (2013)
- Vol. 10 (2012)
- Vol. 9 (2011)
- Vol. 8 (2010)
- Vol. 7 (2009)
- Vol. 6 (2008)
- Vol. 5 (2007)
- Vol. 4 (2006)
- Vol. 3 (2005)
- Vol. 2 (2004)
- Vol. 1 (2003)
Need Help?
Announcements
20 March 2020
MDPI Backs Open Pharma Statement on Open Access
MDPI has endorsed Open Pharma’s Position Statement in support of open access publishing with the aim of advancing medical science and ultimately, improving patient care. Open pharma is a group of research funders, healthcare professionals, publishers, academics, and other healthcare stakeholders.
Since its inception in 1996, MDPI’s efforts have aligned with Open Pharma’s vision of more effective and transparent publishing, collaborating internationally with experts to deliver peer-reviewed online research journals to the scientific community and the general public. MDPI publishes 56 journals in the field of Medicine and Pharmacology and is planning to hold the World Pharma Forum in Basel in 2021.
Published under a Creative Commons License, MDPI’s articles can be freely shared and their content re-used, upon proper attribution. In support of the statement, MDPI will continue to uphold its open access policy and provide fast editorial services to ensure that new medical evidence can be read by everyone, without paywall restrictions.
